NEWS RELEASE-Elpiscience

Choose Language : EN

EN CN

EN | CN

NEWS RELEASE

HOME - NEWS RELEASE

20 Janurary 2021

TRIGR Therapeutics and Elpiscience Biopharmaceuticals Announce $117 Million Exclusive China Licensing Transaction for TR009, a Phase 1B Dual Angiogenic Bispecific Antibody Targeting DLL4/VEGF IRVINE, CA and SHANGHAI, China, January 20, 2021 TRIGR Therapeutics, Inc. (“TRIGR”), a US based clinical stage biopharmaceutical company focused on the development of multi-targeted angiogenic and ...
11 Janurary 2021

Elpiscience to Present at 39th Annual J.P. MORGAN Healthcare Conference Shanghai, China, January 11th 2021. Elpiscience Biopharma Ltd., a clinical stage biotech company focusing on the discovery and development of next-generation cancer immunotherapies, today announced th...
30 December 2020

Elpiscience was Named as One of the Cultivated Unicorn Enterprises of Suzhou Shanghai/Suzhou, China, 30th December 2020. Elpiscience Biopharma Ltd., a clinical stage biotech company focusing on the discovery and development of next-generation cancer immunotherapies, was named ...
28 August 2020

Elpiscience Announces CDE Clearance of IND Application for ES102 Shanghai, China, 28th August 2020. Elpiscience Biopharma Ltd., a clinical stage biotech company focusing on the discovery and development of next-generation cancer immunotherapies, today announced tha...
15 June 2020

Elpiscience Announces IND Submission of ES102 Shanghai, China, 15th July 2020. Elpiscience Biopharma Ltd., a clinical stage biotech company focusing on the discovery and development of next-generation cancer immunotherapies announced today that i...
28 May 2020

Elpiscience Announces Clinical collaboration with Junshi Biosciences Shanghai, China, May 28th, 2020. Elpiscience Biopharma Ltd., a clinical stage biotech company focusing on the discovery and development of next-generation cancer immunotherapies announced today that i...
26 May 2020

Elpiscience to Present at the Jefferies 2020 Healthcare Conference Shanghai, China, May 26th, 2020. Elpiscience Biopharma Ltd., a clinical stage biotech company focusing on the discovery and development of next-generation cancer immunotherapies, today announced that ...
06 Janurary 2020

Elpiscience Appoints Dr. Steve Chin as Chief Medical Officer Shanghai, January 6, 2020. Elpiscience Biopharma, Ltd., a clinical-stage biopharmaceutical company announces the appointment of Steve Chin, M.D. as Chief Medical Officer.
28 December 2019

Elpiscience Completes Series B Financing of USD $100 Million December 28, 2019, Shanghai, China, Elpiscience Biopharma announces the completion of Series B financing of 100 million USD. The round was led by Hyfinity Investments, with participation from Tencent,...
18 November 2019

Elpiscience Appoints Dr. Robert H. Arch as Senior Vice President, Head of Research Shanghai, November 18th, 2019, Elpiscience Biopharma, Ltd., a clinical-stage immuno-oncology company, announced the appointment of Dr. Robert H. Arch as Senior Vice President, Head of Research.

上一页1/3下一页